Clinical Trials Logo

Disease-Free Survival clinical trials

View clinical trials related to Disease-Free Survival.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03923400 Completed - Recurrence Clinical Trials

Jejunoileal vs Gastric GIST in the Era of Imatinib.

Start date: November 1, 2016
Phase:
Study type: Observational

Introduction: Gastrointestinal Stromal Tumors (GISTs) located in the jejunum or ileum (JI-GIST) are considered of worse prognosis compared to other locations. It has been suggested that this dogma should be revised. The aim of this study is to describe the characteristics of jejunoileal GISTs and its prognosis; and to compare them with gastric GISTs in the era of imatinib. Patients and methods: We retrospectively reviewed the clinical histories of all the patients diagnosed with GISTs between January 2000 and November 2016. Clinical and pathological data, as well recurrence, metastatic, disease-free survival (DFS) as overall (OS) rates of patients with JI-GIST or gastric GIST (G-GIST) were collected and compared.

NCT ID: NCT02980185 Completed - Overall Survival Clinical Trials

Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer

Start date: June 2007
Phase: N/A
Study type: Observational

To assess the feasibility, Residual Tumor, complication rate and survival of totally laparoscopic primary cytoreduction in carefully selected patients with Advanced Ovarian Cancer, compared with abdominal primary cytoreduction in a single-Institution, single-surgeon prospective series.

NCT ID: NCT00748358 Completed - Prostatic Neoplasms Clinical Trials

An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

PROSUT
Start date: March 2008
Phase: Phase 2
Study type: Interventional

as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are still responders after 6 cycles will be treated until disease progression, pain progression, unacceptable toxicity or death due to any cause. Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability. Follow-up for up to 1 year from the last dose of sunitinib.